Protocol H8H- MC-LAHD (a) 
 
Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral 
Doses of Propranolol   [STUDY_ID_REMOVED]   Approval Date: 20- OCT -2017 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 1
LY573144Protocol H8H-MC-LAHD(a)
Effect of Lasmiditan on Heart Rate and Blood Pressu re in 
Healthy  Subjects Receiving Oral Doses of Propranolol
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
lasmiditan (LY573144 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commerciall y confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act Exemption 4 and 
may not be reproduced or otherwise disseminated without the written approval of Eli Lilly 
and Company or its subsidiaries.
Lasmiditan (LY573144 )
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly: 27 June 
2017.
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly on date 
provided below.
Approval Date: 20-Oct-2017 GMT
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 2
LY573144Table of Contents
Effect of Lasmiditan on Heart Rate and Blood Pressure in 
Healthy  Subjects Receiving Oral Doses of Propranolol
Section Page
Protocol  H8H -MC-LAHD(a) Effect of Lasmiditan on Heart Rate and 
Blood Pressure in Healt hy Subjects Receiving Oral Doses of 
Propranolo l......................................................................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 17
3.1. Study  Rati onale ............................................................................................................ 17
3.2. Background .................................................................................................................. 17
3.3. Benefit/Risk Assessment .............................................................................................. 19
4. Object ives and Endpo ints.................................................................................................. 20
5. Study  Design ..................................................................................................................... 21
5.1. Overall Design ............................................................................................................. 21
5.2. Num ber of Participants .................................................................................................22
5.3. End of Study  Definit ion............................................................................................... 22
5.4. Scientific Rationale for Study  Design ........................................................................... 22
5.5. Justification for Dose ................................................................................................... 22
6. Study  Popul ation............................................................................................................... 23
6.1. Inclusio n Cri teria.......................................................................................................... 23
6.2. Exclusio n Cri teria........................................................................................................ 24
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 26
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 26
6.3.1. Meals and Dietary  Restri ctions............................................................................. 26
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 26
6.3.3. Activity................................................................................................................ 27
6.4. Screen Failures ............................................................................................................. 27
7. Treatment .......................................................................................................................... 28
7.1. Treatment A dministered ............................................................................................... 28
7.1.1. Packaging and Labeling ....................................................................................... 28
7.2. Method of Treatment Assignment ................................................................................ 28
7.2.1. Timing of Doses ................................................................................................... 29
7.3. Blinding ....................................................................................................................... 29
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 3
LY5731447.4. Dose Modificat ion........................................................................................................ 29
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 29
7.6. Treatment Compliance .................................................................................................29
7.7. Concomitant Therapy ................................................................................................... 29
7.8. Treatment After the End of the Study ........................................................................... 29
8. Discontinuati on Cri teria .................................................................................................... 30
8.1. Discontinuati on from Study  Treatm ent......................................................................... 30
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 30
8.2. Discontinuati on from the Study .................................................................................... 30
8.3. Subjects Lost to Follow -up........................................................................................... 31
9. Study  Assessments and Procedures ................................................................................... 32
9.1. Efficacy Assessments ................................................................................................... 32
9.2. Adverse Events ............................................................................................................ 32
9.2.1. Serious Adverse Events ........................................................................................ 33
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 33
9.2.2. Com plaint Handling ............................................................................................. 33
9.3. Treatment of Overdose .................................................................................................34
9.4. Safety........................................................................................................................... 34
9.4.1. Laborator y Tests .................................................................................................. 34
9.4.2. Vital Signs ........................................................................................................... 34
9.4.3. Electrocardiograms .............................................................................................. 34
9.4.3.1. 12-Lead Electrocardiograms ................................ ........................................... 34
9.4.3.2. Holter Ambulatory  Moni toring ....................................................................... 35
9.4.4. Safety Moni toring ................................................................................................ 36
9.4.4.1. Hepati c Safet y................................................................................................ 36
9.5. Pharmacokinet ics......................................................................................................... 37
9.5.1. Bioanalysis ........................................................................................................... 37
9.6. Pharmacodynamics ...................................................................................................... 37
9.7. Genet ics....................................................................................................................... 37
9.8. Biomarker s................................................................................................................... 38
9.9. Heal th Economics ........................................................................................................ 38
10. Statistical Considerations and Data Analysis ..................................................................... 39
10.1. Sample Si ze Determinat ion.......................................................................................... 39
10.2. Popul ations for Analyses .............................................................................................. 39
10.2.1. Study  Parti cipant Disposit ion............................................................................... 39
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 39
10.3. Statistical Analyses ...................................................................................................... 39
10.3.1. Safety Analyses .................................................................................................... 39
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 4
LY57314410.3.1.1. Clinical Evaluation of Safet y.......................................................................... 39
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 40
10.3.2. Pharmacokinet ic Analyses .................................................................................... 40
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 40
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 40
10.3.3. Cardi ovascular Analyses ...................................................................................... 40
10.3.3.1. Cardi ovascular Param eter Estimat ion............................................................. 40
10.3.3.2. Statistical Inference of Cardiovascular Parameters .......................................... 41
10.3.4. Interim Analyses .................................................................................................. 41
11. References ........................................................................................................................ 42
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 5
LY573144List of Tables
Table Page
Table LAHD.1. Object ives and Endpo ints....................................................................... 20
Table LAHD.2. Treatments Administered ........................................................................ 28
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 6
LY573144List of Figures
Figure Page
Figure LAHD.1. Illustrati on of  study  design for Protocol H8H -MC-LAHD. ..................... 22
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 7
LY573144List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 43
Appendix 2. Clinical Laboratory  Tests ........................................................................ 47
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 48
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 51
Appendix 5. Blood Sam pling Summary ................................
...................................... 52
Appendix 6. Protocol  Amendment H8H -MC-LAHD(a) Summary :  Effect of 
Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects 
Receiving Oral Doses of Proprano lol...................................................... 53
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 8
LY5731441.Protocol Synopsis
Title of Study:
Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy  Subjects Receiving Oral Doses of Propranolol
Rationale: 
In clinical practice, lasmiditan is likely to be coadministered with propranolol, and it is therefore pertinent to 
determine the potential for cardiovascular effects or pharmacokinetic (PK) drug interactions.  Propranolol is known 
to decrease heart rate. Study H8H-MC -LAHD is being conducted to evaluate the cardiovascular effects and PK 
impact of coadministration of lasmiditan with propranolol in healthy subjects.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To evaluate the effects of propranolol alone and in 
combinatio n with lasmiditan on heart rate.Heart rate by Holter ambulatory monitoring.
Secondary
To evaluate the effects of propranolol alone and in 
combinatio n with lasmiditan on blood pressure and PR 
interval.
To explore the tolerability of a single dose of 
lasmiditan alone or in combination with propranolol.
To evaluate the PKof lasmiditan alone and in 
combinatio n with propranolol .
To evaluate the PKof propranolol alone and in 
combinatio n with lasmiditan .PR interval by Holter ambulatory monitoring, systolic 
blood pressure, and diastolic blood pressure.
A summary of the number of treatment -emergent 
adverse events ( TEAEs )and serious adverse event s 
(SAEs ).
Maximum observed drug concentration ( Cmax), time of 
maximum observed drug concentration ( tmax) and area 
under the concentration versus time curve (AUC) from 
time 0 extrapolated to infinity (AUC [0-∞]).
Cmax, tmax, and area under the concentration versus 
time curve during 1 dosing interval ( AUC τ).
Summary of Study Design :  
This is an open -label, fixed -sequence study in healthy subjects to assess the cardiovascular effects of the 
coadministration of lasmiditan with propranolol .  Subjects will receive a single dose of 200 mg lasmiditan on Day 1, 
then receive a single dose of 200 mg lasmiditan coadministered with steady -
state propranolol on Day 9.
Blood samples will be collected predose and up to 48 hours postdose on Days 1 and 9 f or the measurement of 
plasma concentrations of lasmiditan and its metabolites , and predose and up to 12 hours postdose on Days 8 and 9 
for the measurement of plasma concentrations of propranolol .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 9
LY573144Safety will be assessed through reporting of adverse events (AEs) , clinical laboratory evaluations, vital signs 
measurements, 12- lead electrocardiograms (ECGs) , and physical examinations.
Cardiovascular effects will be assessed by Holter ambulatory monitoring and replicate measurements of blood 
pressure at predose, and for 12 hours postdose on Days -1, 1, 8, and 9.
Treatment Arms and Planned Duration for an Individ ual 
Subject :  
All subjects will be assigned to the same treatment sequence.  The planned duration for each individual subject will 
be approximately 45 da ys, including screening .
Number of Subjects:
Approximately 44 subjects may be enrolled so that at least 36 subjects complete the study.
Statistical Analysis:
The primary parameters for the cardiovascular analy ses will be systolic blood pressure, diastolic blood pressure, 
mean hourly heart rate, mean hourly heart rate nadirs, heart rate, and PR interval. Mean hourly heart rates from 
1hour predose to 12hours postdose will be calculated on Days -1, 1, 8, a nd 9 from the Holter monitoring data.  
Negative chronotropic effects will be evaluated using nadir (1 -6 h) ,nadir ( >6 h–12 h), andnadir (1 -12 h), which are 
defined as the lowest mean hourly heart rate during each postdose time period on each day.  Heart r ate and PR 
interval will also be determined on Days -1, 1, 8, and 9 from the 10 -second Holter traces extracted at the time points 
listed in the Schedule of Activities.
Cardiovascular parameters will be evaluated to determine the impact of coadministration of propranolol with 
lasmiditan on blood pressure, heart rate, and PR interval compared to propranolol alone.  Primary  cardiovascular
parameters will be evaluated in a linear mixed -effects model with a fixed effect for treatment (lasmiditan 
coadministered with propranolol [Day 9; test treatment] versus propranolol alone [Day 8; reference treatment]), and 
a random effect for subject.  Least squares (LS) means will be calculated for the t est and reference treatments.  Mean
treatment differences will be present ed along with the corresponding 90% confidence interval (CI) .  Primary  PD 
parameters may be log -transformed prior to the statistical analysis if a review of the data indicates that th e 
assumption of normality is violated.  A similar analysis will be performed to determine the impact of 
coadministration of lasmiditan with propranolol on blood pressure, heart rate, and PR interval compared to 
lasmiditan alone.  The model will include the following treatments:  propranolol coadministered with lasmiditan 
(Day  9; test treatment) versus lasmiditan alone (Day 1; reference treatment).
The impact of coadministration of propranolol with lasmiditan on orthostatic blood pressure and pulse rate will be 
evaluated using descriptive statistics as appropriate.  No formal statistical analysis is planned.
Pharmacokinetic parameter estimates for lasmiditan ,its metabolites, andpropranolol will be calculated by standard 
noncompartmental methods of analysis.
Pharmacokinetic parameters will be evaluated to determine the impact of propranolol coadministration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C max and AUC parameters will be evaluated in a 
linear mixed-effects model w ith a fixed effect for treatment (lasmiditan coadministered with propranolol [Day 9; test 
treatment] versus lasmiditan alone [Day 1; reference treatment]), and a random effect for subject.  The treatment 
differences will be back -transformed to present the ratios of geometric means and the corresponding 90% CI.  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 10
LY573144The t max will be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs and p -values from the Wilcoxon test will be calculated.
A simi lar analysis will be performed to determine the impact of coadministration of a single dose of lasmiditan on 
the steady -state PK of propranolol.  The model will include the following treatments:  propranolol coadministered 
with lasmiditan (Day 9; test trea tment) versus propranolol alone (Day 8; reference treatment). 
Safety parameters will be summarized using descr iptive statistics , where appropriate .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 11
LY5731442.Schedule of A ctivities
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 12
LY573144Study Schedule Pro tocol H8H -MC-LAHD
ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Informed 
ConsentX
Subject 
Admission to 
CRUX
Subject 
Discharge 
from CRUX
Lasmiditan 
AdministrationX, 
indicates 
time = 0X
Propranolol 
AdministrationX X X X X X X
Medical 
Histor yX
Height X
Weight X
Temperature X
Physical Exam
X X X X X X XFull physical examination 
(to include neurological 
examination) at screening, 
Day -1 and follow -upvisit 
only.  Symptom driven 
physical examination for 
all other time points .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 13
LY573144ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Supine Blood 
Pressure and 
Pulse Rate 
(hours)
X XPredose , 
1, 1.5, 2, 
2.5, 3, 4, 
6, 8, 12X X X XPredose, 
1, 1.5, 2, 
2.5, 3, 4, 
6, 8, 12Predose, 
1, 1.5, 2, 
2.5, 3, 4, 
6, 8, 12XBlood pressure and pulse 
rate should be assessed at 
predose on Days 4 to 7 and 
on Day 10.
Time points may be added
if warranted and agreed 
upon between Lilly and the 
investigator. All 
assessments should be 
performed in triplicate , 
with the exception of 
screening . See 
Section 9.4.2 for details .
If multiple procedures take 
place at the same time 
point, the following order 
of the procedure sshould be 
used: ECG, vital signs, and 
venipuncture .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 14
LY573144ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Orthostatic 
Vital Signs 
(hours)
X XPredose,
1, 2Predose, 
1, 2Predose , 
1, 2Last triplicate vital sign can 
be used as the supine vital 
sign for calculation of 
orthostatic changes. If 
multiple procedures take 
place at the same time 
point, the following order 
of the procedure sshould be 
used: ECG, vital signs, and 
venipuncture .  
Time points 
may be added if warranted 
and agreed upon between 
Lilly  and the investigator.
Clinical Lab 
Tests
(including 
serum 
pregnancy 
test)X X X X X XSeeAppendix 2 , Clinical 
Laborato ry Tests, for 
details.   If multiple 
procedures take place at the 
same time point, the 
following order of the 
procedure sshould be use d: 
ECG, vital signs, and 
venipuncture .  
12-lead ECG
(hours)
X XPredose, 
1, 2, 424Predose, 
1, 2, 4Predose, 
1, 2, 424Single ECGs to be taken at 
each time point .  If multiple 
procedures take place at the 
same time point, the 
following order of the 
procedure sshould be use d: 
ECG, vital signs, and 
venipuncture .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 15
LY573144ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Holter 
Ambulatory 
Monitoring
X X X XAmbulatory monitoring 
through the 12-hour time 
point on Days -
1, 1, 8, 
and9.  Mo nitoring on 
Day -1 should be started 
approximately 1 hour prior 
to the anticipated dosing 
time.  Extractions should 
be made at -1, 0.5, 1, 2, 
2.5, 3, 4, 6, 8, and 12 hours 
postdose.  Triplicate ECG 
extractions to be taken at 
each time point.  
Genetic 
Sample XSingle sample for 
pharmacogenetic analysis 
taken prior to/on Day 1
Lasmiditan 
and Metabolite 
PK Samples 
(hours)Predose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 1224, 
3648Predose, 
0.5,1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 1224, 
3648Sampling times are relative 
to the time of study 
treatment administration 
(0min).
If multiple procedures take 
place at the same time 
point, the following order 
of the procedure sshould be 
used: ECG, vital signs,
and venipuncture .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 16
LY573144ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Propranolol 
PK Samples 
(hours) Predose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12Predose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12Sampling times are relative 
to the time of propranolol
administration (0 min).
If multiple procedures take 
place at the same time 
point, the following order 
of the procedure sshould be 
used: ECG, vital signs, 
and venipunc ture.
Abbreviations:  CRU = clinical research unit; ECG = electrocardiogram; ED = early discontinuation; min = minutes; PK = pharma cokinetics. 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 17
LY5731443.Introduction
3.1. Study Rationale
Lasmiditan is a small mo lecule serotonin ( 5-hydroxytryptamine; 5-HT)1Freceptor agonist being 
developed for the acute treatment of migraine.   When administered intravenously (IV) at the 
highest dose of 180 mg (H8H -BD-LACA), lasmiditan produced a small but statistically 
significant dose -related decrease in heart rate and increase in blood pressure, although the 
magnitude of these effects was considered unlikely to be of clinical significance.  Following oral 
administration at doses of up to 400 mg, heart rate again was slight ly reduced, but there were no 
consistent effects on bl ood pressure.  The effects on vital signs were transient, not dose related, 
and unlikely  to be clinically significant given the intended intermittent use of lasmiditan.
Propranolo l is a non -selective β -adrenergic receptor antagonist that is given for migraine 
prophylaxis.  In clinical pract ice, lasmiditan is likely to be coadministered with propranolo l; it is 
therefore pertinent to determine the potential for cardi ovascular effects or pharmacokinetic (PK) 
drug interactions.  β-adrenergic receptor anta gonists (such as propranol ol)areknown to decrease 
heart rate by approximately 17 to 18% (LeWinter et al 1975) .
Propranolo lmetabo lism involves m ultiple cytochrom e P450 
(CYP) pathways , specifically vi a 
CYP2D6, CYP 1A2, and CYP 2C19 , while i t is aweak inh ibitor of CYP2D6 .  Propranolo l may 
also be a moderate inhibitor of CYP1A2 based on its interaction with theophylline , a sensi tive 
CYP1A2 substrate (Miners et al. 1985).  Although the major route of lasmiditan metabo lism in 
humans is non-CYP m ediated ketone reducti on, minor CYP -mediated metabolism viaCYP1A2 
and CYP3A4 wasnoted in vitro .In vitro , lasmidit an has been shown to be a weak CYP2D6 
inhibitor which is not expected to be clinically significant . Taken together, there is a low 
likelihood of a pharm acokinet ic interacti on between lasmiditan and propranolo l.
Study  LAHD is being conducted to evaluate the cardi ovascular effects and PK impact of 
coadministration of a single dose of lasmiditan 200mgwith propranol ol80mg twice daily  (bid) 
in healthy subjects.
3.2. Background
Two Phase 2 studies have been co mpleted wi th lasmidi tan in the acute treatm ent of migraine, 
using doses of up to 45 mg over 20 minutes of the IV formulat ion, and up to 400 mg of the oral 
tablet formulation.  One Phase 3 rando mized, double -blind, placebo controlled trial has been 
completed in the United States (COL MIG -301 [SAMURAI]), where 1856 patients were 
rando mized to 100 mg lasmiditan (630 subjects), 200 mg (609 subjects), or placebo 
(617 subjects), respectively. In the SAMURAI study , both 100 m g and 200 m g doses of orally 
administered lasmiditan achieved superior 2- hour pain free rate and the relief o f most 
bothersome migraine symptoms (nausea, phonophobia, and photophobia) compared to placebo.
Across the complet ed Phase 1, 2, and 3 clinical studies, doses of 0.1 mg to 400 mg o f lasmiditan 
were evaluated in healt hy subjects or patients with migraine.  Lasmiditan has been administered 
to 213 healthy subjects in five Phase 1 studies:  as IV doses ranging from 0.1 to 180mg 
(H8H -MC-LACA ; 40 subjects ); as an oral or sublingual so lution with doses ranging from  25 to 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 18
LY573144400mg and 1 to 32 mg, respectively (COL MIG -102; 60 subjects); as an oral solut ion at a dose 
of 200 mg or as oral tablets at doses of 50 or 400mg (COL MIG -103; 44 subjects); as oral 
tablets at a dose of 200 mg (COL MIG -104; 30 subjects); and as oral tablets at doses of 100 or 
400mg (COL MIG -105; 56 subjects).  Two Phase 2 studies have been co mpleted, evaluat ingIV 
doses ranging fro m 2.5 to 45 mg(COL MIG -
201) and oral  tablets ranging from 50 to 400 mg 
(COL MIG -202).   In the Phase 3 SAMURAI study (COL MIG -301) , 1856 patients aged 18 to 
79years received at least 1 dose of lasmiditan or placebo , with 1239 pati ents receiving oral 
tablets of  100 or 200 mg lasmi ditan.  The most frequent ly reported lasmiditan treatment -
emergent adverse events (TEAEs) included dizziness (12.5 to 16.3%), paresthesia (5.7 to 7.9%), 
somno lence(5.4 to 5.7%) , fatigue (3.1 to 4.1%) , , and, compared to placebo where 3.4%, 2.1%, 
2.3%, and0.3% of subjects reported each event, respect ively.   The m ajority of these TEAEs 
were mild or moderate in severit y and none led to subject withdra wal.  
Oral tablet doses of lasmiditan up to 400 mg did not result in any clinically relevant changes in 
ECG s(including QT interval/corrected QT interval [QTc]) or vital signs f ollowing 
administration to healthy subjects.  There was a consistent small decrease in heart rate at oral 
doses of 100 to 400 mg lasmiditan though this was not considered to be clinically significant 
(COL MIG -102, COL MIG -103, COL MIG -105).  A single SAE of dizziness wit h sinus 
bradycardia after an oral dose of 200mg lasmiditan was reported; this event was moderate in 
severit y, occurred approximately 30 minutes after dosing wit h lasmidi tan 200 mg, and was 
considered to be probably  related to l asmidi tan.  The subject was admitted to hospital for 
overnight observation fo llowing review by the hospital emergency  room  physician.
In the thorough QT study  (COL MIG -105) in healthy  subjects, no cli nically significant changes 
in blood pressure, heart rate, or 12 -lead ECG were observed at the 100 or 400 mg dose levels.  
Lasmiditan caused no significant QT prolongat ion at ei ther dose.
In healthy subjects, peak plasma concentrations of lasmiditan were o bserved approximately 1 to 
2.5 hours after a single oral doses ranging from 25 to 400 mg, and the geom etric mean terminal  
half-life was approximately 4 to 6 hours.  Lasmidit an exhibited dose -linear PK; low to m oderate 
inter-subject variabilit y in exposure was observed across doses (coefficient of variat ion [%CV]
up to 61% and 45% for maximum observed drug concentration [Cmax]and area under the curve 
[AUC ], respectively (COL MIG -102).  Renal clearance of lasmiditan was low ,with 
approximately  2% of  the parent dose recovered by  24 hours postdose.  Co-administration of 
lasmiditan wit h a high fat diet led to a delay in median time o f maximum observed drug 
concentration ( tmax) value by approximately 1 hour and a modest (~20%) increase in lasmiditan 
maximum o bserved drug concentration ( Cmax) and AUC values, relative to that under fasted 
condi tions.
Hum an metabolism has been invest igated using liquid chromatography  with tandem mass 
spectrometric detection ( LC-MS/MS )following oral  dosing wi th lasmidi tan, where up to 11 
metabo lites were detected i n plasma and urine, including 3 major metabo lites (M7, M8, and 
M18).  These metabolites lacked significant pharmacological act ivity at the 5 -HT 1Freceptor and 
were generally  considered to be pharm acologically inact ive.  The relat ive proportions of 
metabo lites to intact l asmidi tan remained reasonably  constant throughout the oral dose range 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 19
LY573144studi ed and thei r PK w asapproximately linear.  The half -life o f the metabo lites ranged from  
~4.5 hours to >12 hours.
3.3. Benefit/Risk Asse ssment
Inthis study ,the effects of propranol olalone, lasmidi tan al one, and propranol ol in combinat ion 
with lasmidi tanon bl ood pressure , heart rate, andPR interval will be evaluated in healthy 
subjects .There is no ant icipated therapeutic benefit for the subjects.
Lasmiditan has been tolerated by  healthy subjects as single oral doses up to 400 mg.  No 
clinically significant safety  or tol erabilit y concerns have been ident ified in subjects to date for 
lasmiditan up to the highest single oral dose given ( 400 m g).  Dosing of l asmidi tan in this study  
will be conducted in an inpat ient setting, and subjects will be mo nitored in house for at least 
48hours after dosing.
Propranolo lis a marketed drug and will be administered within the reco mmended dose regimen 
for clinical use (80 m g bid) ; this dose regimen has been tolerated in previous PK/PD studies in 
healt hy subjects (for example, Fleishaker et al. 2001; Marathe et al. 1998; Peck et al. 1997; Scott 
et al. 1991) .  Dosing of propranol olin this study  will be conducted in an inpat ient setting, and 
subjects will be monitored in house for at least 24 hours after completing dosing.
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated adverse events (AEs) of lasmidi tanare to be found in the Invest igator’s Brochure 
(IB).  
More detailed informat ion about the known and expected benefits and ris ks of  propranol olmay 
be found in the fo llowing:  Pati ent Inform ation Leaflet or Summary o f Product Characterist ics.
H8H -MC -LAHD (a ) C l in ica l  P ha rmaco logy  P ro toco l Page  20 
LY573144 4 . Ob jec t ives and  Endpo in ts 
T ab l e LAHD .1 s h ow s  t h e  o b j e c t i v e s  a n d  e n d p o i n t s  o f  th e  s tudy .
Tab le LA HD .1 . Ob jec t ives  and  Endpo in ts 
Ob j e c t i v e s Endp o in t s 
P r im a r y 
T o  e v a l u a t e  t h e  e f f e c t s  o f  p r o p r a n o l o l a lo n e  a n d  i n  
c om b in a t io n  w i t h  l a sm i d i t a n o n  h e a r t  r a t e . He a r t  r a t e  b y  H o l t e r  am b u l a t o r y  m o n i t o r i n g . 
S e c ond a r y 
T o  e v a l u a t e  t h e  e f f e c t s  o f  p r o p r a n o l o l  a l o n e  a n d  i n  
c om b in a t io n  w i t h  l a sm i d i t a n  o n  b l o o d  p r e s s u r e  a n d  PR  
i n t e r v a l . 
T o  e x p l o r e  t h e  t o l e r a b i l i t y  o f  a  s i n g l e  d o s e  o f  l a sm i d i t a n  
a lon e  o r  i n  c om b i n a t i o n  w i t h  p r o p r a n o l o l . 
T o  e v a l u a t e  t h e  PK o f  l a sm i d i t a n  a l o n e  a n d  i n  
c om b in a t io n  w i t h  p r o p r a n o l o l .
T o  e v a l u a t e  t h e  PK o f  p r o p r a n o l o l  a l o n e  a n d  i n  
c om b in a t io n  w i t h  l a sm i d i t a n .PR  i n t e r v a l  b y  H o l t e r  am b u l a t o r y  m o n i t o r i n g ,  s y s t o l i c  
b l o o d  p r e s s u r e ,  a n d  d i a s t o l i c  b l o o d  p r e s s u r e . 
A  s umm a r y  o f  t h e  n um b e r  o f  TEAE s  a n d  SAE s .
Cm a x ,  t m a x ,  a n d  AUC ( 0 -∞ ) . 
Cm a x ,  t m a x ,  and  AUC d u r i n g  1  d o s i n g  i n t e r v a l  ( AUC τ) . 
E xp l o r a t o r y Ob j e c t i v e s 
T o  e v a l u a t e  t h e  e f f e c t s  o f  l a sm i d i t a n  a l o n e  a n d  i n  
c om b in a t io n  w i t h  p r o p r a n o l o l  o n  o r t h o s t a t i c  c h a n g e s  i n  
b l o o d  p r e s s u r e  a n d  p u l s e  r a t e . 
T o  e v a l u a t e  t h e  PK  o f  t h e  m e t a b o l i t e s  M 8 ,  M 7 ,  a n d  M 1 8  
in  h e a l thy  s u b j e c t s  f o l l ow i n g  a  s i n g l e  2 0 0 -m g  o r a l  d o s e  
o f  l a sm i d i t a n  a l o n e  a n d  i n  c om b i n a t i o n  w i t h  p r o p r a n o l o l . O r t h o s t a t i c  c h a n g e s  i n  s y s t o l i c  b l o o d  p r e s s u r e ,  d i a s t o l i c  
b l o o d  p r e s s u r e ,  a n d  p u l s e  r a t e . 
PK  p a r am e t e r s :   C m a x ,  t m a x ,  a n d  AUC ( 0 -∞)
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 21
LY5731445.Study  Design
5.1. OverallDesign
This is an open -label , fixed -sequence study in healthy  subjects to assess the cardiovascular 
effects of coadministration of lasmiditan with propranol ol. 
Screening Period: 
All subjects will part icipate in a screening visit up to 28 days prior to the first lasmiditan dose.  
Dosing Period:
Subjects will be admitted to the clinical research unit (CRU) on Day  -2.  On Day  1 , subjects will 
receive a single dose of 200 m g lasmidit an, then receive propranolo l (immediate rel ease 
formulation; half -life approximately  3 to 6 hours ) 80mg bid on Days 4 through 10and a single 
dose of 200 m g lasmiditan coadministered wi th propranol ol on Day  9.  Subj ects will reside in the 
CRU from Day -
2until Day 11 when they may be discharged from  the CRU following 
completion of all study  procedures , at the invest igator’s discretion .
Study  governance considerations are described in d etail in Appendix 3 .
Blood sam ples will be collected predose and up to 48 hours postdose on Days 1and 9for the 
measurement of plasma concentrations of lasmidi tanand i ts metabo lites. Blood sam ples will 
also b e collected predose and up to 12hours postdose on Day s 8and 9for the m easurement of 
plasma concentrations of propranol ol.
Safety assessments performed during the study  will include AEs, clinical laboratory evaluat ions, 
vital signs measurements, 12-lead ECGs, and physical examinat ions.
Cardi ovascular effects will be assessed by  Holter ambulatory  monitoring and replicate 
measurement sof blood pressure at predose, and for 12 hours postdose on Days -1, 1, 8, and 9.
Follow
-up Peri od
Subjects will attend a follow-up visit approximatel y 7 days after the l ast dose .  
Figure LAHD .1illustrates the study  design.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 22
LY573144Figure LAHD.1. Illustration of study design for Protocol H8H -MC-LAHD.
5.2. Number of Participants
Approximately 44 subjects m ay be enrolled sothat at least36subjects complete the study.   
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedur e shown in the Schedule o f 
Activities(Secti on
 2) for the last subject.
5.4. Scientific Rationale for Study Design
The study  has an open -label, fixed
-sequence design in which each subject receives lasmiditan 
alone, propranol ol alone, and lasmiditan coadministered with propranolo l, allowing each subject 
to act as his/her own control for safet y and PK comparisons.  A sin gle 200mg dose of l asmidi tan 
was selected as it isthe highest potential reco mmended dose for lasmiditan . The washout period 
between lasmidi tan doses of 8 days is considered sufficient based on the half -life of lasmiditan of 
approximately  4 to 6 hours. Propranolo l takes approximately  1 to 4 hours to reach maximum 
concentrations in the blood and has a pl asma half -life of approximately 3 to 6 hours, although its 
biological  effects m ay last l onger (Propranol ol SPC, 2016) ; therefore, it will be administered 
according to a twicedaily ( bid)dosing regimen .  Propranolo l will be administered twice daily for 
7 day s, wi th a single dose of lasmiditan coadminist ered on the 6thday, to ensure that propranolo l 
concentrations are at steady-state at the time of lasmidit an dosing and throughout the lasmiditan 
PK sampling period (48 hours postdose).  
5.5. Justification for Dose
The dose level o f 200 m g lasmidi tan has been well tol erated in previous studies of healt hy 
subjects .  Thi s dose l evel is expected to be the highest potential reco mmended single dose for 
lasmiditan .
The dose of propranolo l (80 m g bid) i s within the range used in clinical pract ice, and this dose 
regimen has been tolerated by healthy subjects in previous PK/PD studies (for example, 
Fleishaker et al. 2001 ; Marathe et al. 1998; Peck et al . 1997; Scott et al. 1991).Study  day Follow -up 
7days after 
last dose2 3 4 9 -28
PropranololLasmiditan Lasmiditan
Screening1 10
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 23
LY5731446.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests, and ECG. 
The nature of  any condi tions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occu r up to 28 days prior to enrollment (Day  1).  Subj ects who are not enrolled 
within 28 days o f screening may be subject ed to an additional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and /orenrollment:
[1] are overtly h ealthy males or females, as determined by  medical history  and 
physical examinat ion .  
[1a]male subjects:
are not required to adhere to con tracepti ve requi rements . 
[1b] fema le subjects:
of childbearing potential, must test negative for pregnancy  at screening, 
and agree to use a reliable method of birth con trol during the study  and f or 
1 week following the last dose of lasmiditan.  Reliable methods of 
contraception for female subjects of childbearing potential include the use 
of stable horm onal contracepti on, bilateral tubal ligation, intrauterine 
device, or di aphragm  with spermicide along wit h male partner’s use o f 
male condo m with spermicide.
ofnon-child bearing potential, i.e.,postmenopausal or permanent ly sterile 
following hysterectomy, bilateral salpingectomy ,or confirmed tubal 
occlusion (not tubal  ligation), as determined by medical his tory.  
Postmenopausal  is defined as spontaneous am enorrhea for at least 
12months, and a serum follicle -stimulat ing hormone (FSH) level greater 
than 40 m IU/mL, unless the subject is taking hormone replacement 
therapy (HRT) .
[2] are a ged18to 65 years o ldat the time of screening.
[3] have a body  mass index (BMI) of 19.0 to 35.0kg/m 2, inclu sive, at the time of 
screening.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 24
LY573144[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th accep table deviat ions that are 
judged to be not clinically significant by  the investigator .
[5] have venous access sufficient to allow for blood sampling as per the protocol .
[6] are reliable and willing to make themselves available for the duration of the 
study and are willing to follow study  procedures .
[
7]have given written informed consent approved by Lilly and the ethical review 
board (ERB) governing the site.
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[
8]are invest igativesite personnel  direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling.
[
9]are Lilly or Covance empl oyees.
[
10]are currently enrolled in a clinical  study  involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.  
[11] h ave known allergies to lasmiditan, propranolo l, related compounds or any  
components of the formulat ionof lasmidi tan or propranol ol.
[12]are persons who have previously received th e investigat ional product in this 
study , withdrawn from  this study  or received lasmiditan in any other study  
investigat ing lasmiditan.
[13]have participated (dosed with invest igational product) , within the last 30 days, 
in a clinical study  involving an invest igational product.  If the previous 
investigat ional product has a long half -life, 5 half -lives or 30days (whichever 
is longer) should have passed .
[
14] have as history  of, or ECG findings of, clinically  significant brady cardia, heart
block, tachy  or brady  arrhy thmias, sick sinus syndrome/sinoatrial blo ck, or 
second or third
-degree heart bl ock, or have any otherabnormalit y in the 
12-lead ECG that, in the opinio n of the invest igator, increases the risks 
associ ated wi th parti cipat ing in the study . 
[15]have an abnormal supine blood pressure, defined as systolic blood pressure 
<95 or >140 mmHg or diastoli c blood pressure <65 or >90 mmHg at 
screening .  After screening, vital sign eligibilit y will  be done at the di scret ion 
of the invest igator .  Addit ional assessments may  be perform ed to confirm 
eligibilit y.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 25
LY573144[16] have a history  of syncope, presyncope, uncontr olled vertigo, postural 
dizziness, or at ri sk for falls, as judged to be clinically  significant by  the 
investigator, or have orthostatic decreases in systolic blood pressure of 
>20mmHg, or have orthostatic decreases in diastolic blood pressure of 
>10mmHg at screening.  May  be repeated if asymptomat ic.
[17] have a supine pulse rate of <50or >90 bpm at screening .  Up to 2 additional 
assessments may be performed to confirm eligibility .  
[18] have an est imated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2.
[19] ha ve significant history  of or current card iovascular, respiratory (including 
bronchospasm or bronchial asthma, or chronic obstructive airways disease) , 
hepat ic, renal, gastrointest inal, endocrine, hematological, or neurological 
disorders capable o f significant ly altering the absorpti on, m etabolism , or 
eliminat ion of drugs; of constituting a risk when taking the study  medicat ion; 
or of interfering wit h the interpretation of data .  Appendectomy, splenectomy, 
and cho lecystectomy are considered as acceptable.
[
20] have a history  of or current pheochromocy toma.
[
21] show evidence of significant active neuro psychiatric disease (for example, 
manic depressive il lness, schizophrenia, depressio n).
[
22] show a history  of central  nervous sy stem  (CNS) condit ions such as strokes, 
transi ent ischaemic attacks, significant head trauma, CNS infect ions, 
migraines, brain surgery  or any  other neurol ogical  condi tions that, in the 
opinio n of the invest igator, increases the risk of participating in the study
.
[23] currently use, or within the past 1 y earused recreati onal drug s, or showed 
evidence of substance dependence within the past 6 months based on history  
at screening visi
t.
[24] s how evidence of human immunodeficiency  virus (HIV) infection and/or 
positive human HIV ant ibodies .
[
25] s how evidence of hepatit is C and/or positive hepat itis C ant ibody .
[
26] s how evidence of hepatit is B and/or positive hepat itis B surface antigen.
[
27] are wom en with a posi tive pregnancy test or women who are l actating .
[28] intend to use over -the-counter or prescript ion medication, dietary  supplements
within 14 days pri or to d osing and unt il study  discharge (apart from  
occasi onal acetamin ophen or HRT ).
[29] h ave donated blood of more than 500 mL within 1 month prior to the
screening visit.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 26
LY573144[30] have an average weekly  alcoh ol intakethat exceeds 21 units per week (males 
agedup to 65years) and 14 units per week (females and males over 65 years ), 
or are unwilling to stop alcoho l consumpt ion48 hours prior to dosing and 
whilst resident at the CRU.  At all other times, subjects must consume no 
more than 2 unit s per day (1 uni t = 12 oz or 360 mL of beer; 5 oz or 150 mL 
of wine; 1.5 oz or 45 m L of distilled s pirits).
[31] have a clinically  significant abnorm ality in the neurol ogical  examinat ion.
[
32] are unwilling to refrain fro m tobacco -or nicotine -containing products from 
3months pri or to screening unt il discharge fro m the study .
[33]Have any history  or hy persensi tivity to food or m edications.
[
34] in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [1] through [7] define a healt hy population suitable for evaluat ion in a Phase 1 study.  
Criteria [8] and [9] prevent conflict of interest in study  parti cipants.  Cri teria [10] through [ 33] 
predominant ly exclude medical condit ions, m edicati on intol erance, and concomitant medicat ion 
use that m ay conf ound the assessment of study  endpoints .
6.3. Lifestyle and/or Dietary Requirements
Throughout the stud
y, subjects m ayundergo medical assessment sand review of compliance with 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Lasmiditan and propranolo l will be administered after an overnight fast of at least 8hours.  On 
intensive PK sampling days (Days 1, 8 and 9), s ubjects will abstain fro m water 1 hour before and 
after dosing (except for water given with the dose).  Subjects will remain fast ing for 3 hours 
postdose, at which time a meal will be served.
Subjects m ay be permi tted to consum e a light breakfast at 1 hour postdose at the discret ion of the 
investigator on all other day s.
6.3.2. Caffeine, Alcohol, and Tobacco
Caffeine –Subjects will refrain fro m consuming xanthine -or caffeine -containing food and 
drinks fro m 48 hours prior to admissio n, and while resident at the CRU.
Alcohol –Subjects will not consume alcoho l for 48 hours prior to admissio n, and while resident 
at the CRU.   At all other times, subjects must consume no more than 2 unit s per day  
(1unit= 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL o f distilled s pirits).
Tobacco –Subjects will refrain fro m smoking from 3 mo nths prior to screening until d ischarge 
from the study .  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 27
LY573144Grapef ruit–Subjects will refrain fro m consuming grapefruit and grapefruit -containing products 
from 7 days pri or to Day  1and unt il study  discharge.
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to a dmissio n until after the fo llow-up 
visit.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen fa ilure) m ay not be 
re-screened . 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 28
LY5731447.Treatment
7.1. Treatment Administ ered
Invest igational products used in this study  are shown in TableLAHD .2.
Tablets of lasmiditan and propranol ol will be administered orally wit h approximately 240 mL o f 
room  temperature water ,in a sitting posit ion.  Tablets of lasmiditan will be administered in the 
morning o f each dosing day ,and t ablets of propranolo l will be administered in the morning and 
evening , approximately  12 hours apart, of each dosing day .  
Subjects will not be allow ed to lie 
supine for 2hours after dosin g, unless clinically  indicated or for study  procedures.   
TableLAHD.2. Treatment sAdministered
Treatment Name Lasmiditan Propranolol
Dosage Formulation film-coated tablet film-coated tablet
Unit Dose Strength /Dosage 
Level(1200-mg) tablets/
200 mg lasmiditan(1 80-mg) tablets/
80 mg propranolol
Route of Administration Oral Oral
Dosing Instructions 1 tablet taken in the morning of 
Days 1and 91 tablet taken in the morning and evening of 
Days 4-10
The invest igator or designee is responsible for:
explaining the correct use of the investigational product(s) to the site personnel ;
verifying that instructions are fo llowed properly ;
maintaining accurate records of investigational product dispensing and co llection;
and returning all unused medicat ion to Lilly or its designee at the end of the study .
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Each tablet of lasmiditan contains 200mg of act ive ingredient and is provi ded as bulk suppl iesin 
bottles.  Propranolo l will be sourced by  the invest igative site.
The invest igational product will be labeled according to the country’s regulatory requirements.
7.2. Method of Treatment Assignment
All subjects will receive the same treat ments in the same sequence.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 29
LY5731447.2.1. Timing of Doses
Doses of propranolo l will be administered at approximately  the same time on each dosing day
(every  12 hours) .  On study  days where l asmidi tan and propranol ol are coadministered (Day  9), 
propranolo lshoul d be administered immediately prior to the lasmiditan dose.  Both lasmiditan 
doses should be administered at approximately the same time of day. The actual  time of all dose 
administrations will be recorded i n the subject’s electroni ccas
e report for m (eCRF).
7.3. Blinding
This is an open -label study .
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study .
7.5. Preparation/Handling/Storage/ Accountability
The invest igator or designee must confirm all investigat ional product was received in good
condi tion, and any  discrepancies are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study  may receive invest igational product or study  materials, 
and only  authori zed si te staff may  supply  or administer invest igational product .All 
investigat ional product should be stored in a nenvironm entally  controlled and mo nitored (m anual  
or automated) area in accordance wit h the labeled storage condit ions wit h access limited to the 
investigator and authorized site staff.
Theinvest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Comp liance
The invest igational product will be administered at the clinical site, and documentation of 
treatm ent administration will occur at the site.
7.7. Concomitant Therapy
In general ,concomitant m edicat ion shoul d be avo ided;however ,acetaminophen (maximum 
2g/24 hours) may be administered at the discretion of the invest igator for treatment of headaches 
etc.  Contraceptive medicat ion is permitted as per the inclusio n criteria.  Hormone replacement 
therapy  is also allowed.  
If the need for concomitant medicat ion (other than acetaminophen or HRT ) arises, inclusion or 
continuat ion of the subject may be at the discret ion of the invest igator after consultation wit h a 
Lilly clinical pharmaco logist,clinical research physician (CRP ), ordesignee .  Any  medicat ion 
used during the course of the study  must be documented.
7.8. Treatment After the End of the Study
Not applicable.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 30
LY5731448.Discontinuation Criteria
Subjects discontinuing fro m the study  prematurely for any  reason must com plete adverse event 
and follow-up procedures per Secti on 9.2of this protocol .
8.1. Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal liver tests should be considered by 
the invest igator when a subject meets 1 of the f ollowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
alanine aminotransferase ( ALT ),aspartate aminotransferase (AST) >5×ULN ( upper limit 
of norm al)
ALT or AST > 3×ULN sustained for more than 2 weeks
ALT or AST >3 ×ULN and total bilirubin level (TBL) >2×ULN orINR >1.5
ALT or AST >3 ×ULN the appearance of fatigue, nausea, vo miting, right upper
-quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP ) >3×ULN
ALP>2.5× ULN and TBL > 2×ULN
ALP>2.5 ULN with the appearance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)
8.1.1. Discontinuation of Inadve rtently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not meet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist/CRP or 
designee and the invest igator to determine if the subject may continue in the study .  If both agree 
it is medically appropri ate to continue, the invest igator m ust obtain documented approval from 
the Lilly  clinical  pharmacol ogist/CRP or desi gnee to allow the inadvertently enrolled subject to 
continue in the study  with or wi thout continued treatment with invest igational product.
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator d
ecides that the subject should be discontinued from the study
Subject Decisio n
othe subject requests to be withdrawn fro m the study .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 31
LY5731448.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she fails to return for a scheduled visit and 
is unable to be contacted by  the study  site.  Si te personnel are expected to make diligent attempts 
to con tact subjects w ho fail to return for a scheduled visit or were otherwise unable to be 
followed up by  the si te.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 32
LY5731449.Study Assessments and Procedures
Section 2 lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the clinical laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laborato ry tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
This sect ion is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt
h care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the subject to discontinue the invest igational product before 
completing the study.  The subject should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the inve stigator.
After the informed consent form ( ICF) is signed, s tudy site personnel  will record ,via eCRF ,the 
occurrence and nature of each subject’s preexist ing conditions.   Addit ionally , site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment or a study  procedure, taking into account co ncomitant 
treatm ent or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the invest igational product and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 33
LY5731449.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or sign ificant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe subject or may requi re interventi on to prevent 
one of the other outcom es listed in the definit ion above.
Study  site personnel  must al ert the Lilly  CRP /clinical pharmaco logist, or its desi gnee, of  any 
SAE as soon as pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Subject Safet y,or its designee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notifi cation requi rement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study  (the subject summary e CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to investigat ional product ) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to invest igational product or procedure.  Lilly  
has procedures that will be fo llowed for the recording and expedited reporting of SUSARs that 
are consistent with global regulations and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical trials in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 34
LY573144Subjects should be ins tructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of lasmiditan is consi dered any dose higher than the 
planned study  dose. There i s no specific ant idote for lasmiditan.  In the event of overdose, the 
subject should receive appropriate supportive care and AEs should be documented.
No drug interaction studies in humans have yet been performed with lasmiditan.
9.4. Safety
9.4.1. Laboratory Tests
For ea ch subject, clinical laborato ry testsdetailed in Appendix 2 shoul d be conducted according 
to the Schedule of Activities (Secti on2).
9.4.2. Vital Signs
For e achsubject, vital signs m easurements shoul d be conducted according to the Schedule of 
Activities (Secti on
 2).  Vital signs measurem ents shoul d be c onducted within appr oximately  
20minutes of the no minal t imepo int.
Blood pressure and pulse rate should be measured after at l east 5minutes supine.   All supine 
blood pressure and pulse rate measurements except for screening will be done in triplicates at 
approximately  1-minu te intervals.  Where possible, t he last triplicate vital sign can be used as the 
supine vital sign for the calculat ion of orthostatic changes.   Vital signs m easurements shoul d be 
taken fro m the non -dominant and opposite armas used for PK sampling whenever possible , and 
for each individual subject the same cuff size should be used throughout the study  for 
measurements of blood pressure.
Where orthostati c measurements are required, subjects shoul d be supine for at least 5 minutes, 
and then subjects shoul dstand, and standing blood pressure will be measured after 2 minutes; no 
longer than 3 minutes .
In the event of a positive asymptomatic orthostatic response, repeats are at the investigator ’s 
discreti on.
If the subject feels unable to stand, supine vital signs only  will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured if warranted .
9.4.3. Electrocardiograms
9.4.3.1. 12-Lead Electrocardiograms
For each subject, single 12-lead digital safet y ECG swill be co llected according to the Schedule 
of Activities(Secti on
 2).  Electrocardi ograms should be collected within approximately  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 35
LY57314420minutes of the no minal t imepo int.  Electrocardiogram s may  be obtained at addit ional times, 
when deemed clinically  necessary .
Electrocardiograms must be recorded before collecting any blood samp les.  Subjects must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion.  All ECGs recorded should be stored at the investigat ional site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for imme diate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the subject for symptoms (for examp le, pal pitations, near 
syncope, syncope) to determine whether the subject can continue in the study.  The invest igator 
or qualified designee is responsible for determining if any change in subject management is 
needed and must document his/her review of th e ECG printed at the time of evaluat ion from at 
least 1 of the replicate ECGs fro m each time po int.
It is recognized that the ECG interpretations by the invest igator (or qualified designee) and the 
cardi ologist at the central  ECG l aboratory  may be different.  Interpretation of the ECG by  the 
investigator (or qualified designee) will be used for study entry  and imme diate subject 
management. 
9.4.3.2. Holter Ambulatory Monitoring
Continuous 12 -lead Holter recordings over 12 hours will be performed according to the Schedule 
of Activities (Secti on 2) .  Extractions should be performed within approximately 30minutes of 
the nominal t imepo int.
Subjects m ust be in a quiet atmosphere wit hout significant external st imulat ion (TV, internet, 
etc.), in a supine posit ion for at least 5 to 10 minutes before the specified ECG collection t imes 
indicated in the Schedule of Act ivities, and remain supine but awake during EC G collect ion and 
for at least 10 minutes afterward.  Subjects should be encouraged to remain still, if possible, 
during thi s time.
Digital recordings of all peri ods of  continuous ECG recordings in individual subjects will be 
transferred to a central ECG la boratory  designated by  Lilly .  The ECG l aboratory  will perform 
qualit y control  checks for the time points of interest (for example, acquisit ion qualit y for abili ty 
to measure/interpret, demographics, and study  details) and extract 3 unique 10 -second ECGs a t 
the times listed in the Schedule o f Activities (Sect ion
 2).  
The ECG l aboratory  will then store the 12 -hour recording as well as the extracted 1 0-second 
ECGs, and a cardio logist at the central ECG laboratory  will conduct a full overread (including 
the measurement of all intervals) on one of the replicates that were extracted.  For each set of 
replicates, the cardio logist will determine the RR and QT intervals and heart rate on the ECGs 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 36
LY573144that were not fully overread.  No reports will be issued fro m the central  ECG l aboratory  back to 
the sites for any  ECGs.
All data from the overreads will be placed in a Lilly or Contract Research Organizat ion databas e 
for analy tical and study  report purposes.
Interpretations of the ECG at the central laboratory will be used f or data analysis and 
report -writing purposes.
9.4.4. Safety Monitoring
The Lilly clinical pharmaco logist or CRP /scientist will mo nitor safety  data throu ghout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or CRP will periodically  review the following data:
trends in safety  data
laboratory  analy tes 
AEs
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Subject Safet y therapeuti c area physician or clinical research scient ist.
9.4.4.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3×ULN, ALP ≥2×ULN , or el evated total bilirubin 
≥2×ULN, hepat ic monitoring tests ( Appendix 4 ) shoul d be repeated wi thin 3 to5 day s including 
ALT, AST, ALP, TBL, conjugated bilirubin , gamma -glutamyl transferase ( GGT ),and creatinine 
phospho kinase (CPK) to confirm the abnormalit y and to determine if it is increasing or 
decreasing.  If the abnormalit y persists or worsens, clinica l and laboratory  monitoring shoul d be 
initiated by  the invest igator based on consultation with the Lilly clinical pharmaco logist or CRP .  
Moni toring shoul d continue until levels normalize and/or are return ingto approximate baseline 
levels. 
Addit ional safety data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥ 5× ULN on two or more consecutive blood tests
elevated serum TBL to ≥ 2×ULN (except for cases of known Gilbert’s syndro me)
elevation of serum  ALP to ≥ 2×ULN o n 2or more consecutive blood tests 
subject discontinued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepatic event considered to be a SAE.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 37
LY5731449.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2) , venous blood samples 
of approximately  2mL each will  be collected to determine the plasma concentrations of 
lasmiditan and i ts metabo lites, and venous blood samples of approximately  2 mL each will be 
collected to determine the plasma concentrati ons of proprano lol.  A maximum o f 3 samples each 
may be collected for analysis of lasmiditan or proprano lol at addi tional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.   
The actual  date an d time (24- hour clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of lasmiditan and 3majo r metabo lites will be assayed using a validated LC-
MS/MS method. 
Concentrations of propranol ol will be assayed using a validated LC-MS/MS method. 
Bioanaly tical samples collected to m easure invest igational product and metabolite concentrati ons 
will be retained for a maximum o f 2 yearsfollowing last subject visit for the study .  During this 
time, samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism and/or protein binding work.
9.6. Pharmacodynamic s
Not applicable.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic an alysis as specified in the Schedule of 
Activities(Secti on2), where local regulat ions allo w.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate var iable exposure or response to 
lasmiditan and to invest igate genet ic variants thought to play a role in migraine .  Assessment of 
variable response may include evaluation of AEs or differences in efficacy .  
All samples will be coded with the subject number.   These samples and any data generated can 
be linked back to the subject only by the invest igativesite personnel .  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
selected by Lilly or i ts desi gnee .  This retenti on peri od enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment oflasmiditan or after lasmidi tanis commercially available.  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 38
LY573144Molecular techno logies are expected to improve during the 15 y ear storage peri od and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarker s
This sect ion is not applicable for this study.
9.9. Health Economics
Thissection is not applicable for this study.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 39
LY57314410. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Up to 44 subjects may be enro lled to ensure 36subjects complete the study .  Assuming a 
standard deviat ion for the change in heart rate of 10.9 (based on previous studies
[H8H -MC-CD-LAHO and H8H -CD-LAHJ] ), this will result in a 90% probabilit y that the 
half-width of the 90% CIabout the mean within-subject change is no larger than 5bpm.
Subjects who are randomized but do not complete the study may be replaced to ensure that 
enough subjects complete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed des cripti on of  subject dispos it
ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subjects’ age, sex, weight, height, BMI, race, and other demographic characterist ics will be 
recorded and summarized using descript ive statist ics.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet icanalyses will be conducted on data fro m all subjects who receiv eat least one 
dose of lasmidi tan or propranol ol and have evaluable PK.  
Cardi ovascular analyses will be conducted on data fro m all subjects who have the relevant test 
and reference treatment measurements.
Safety analyses will be conducted for all enro lled subjects, whether or not they  com pleted all  
protocol  requi rements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PKanalysis purposes to 
avoid issues with post -hoc analyses and inco mplete di sclosures of an alyses.   
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with investigational product as perceived by the investigator.  Symptoms reported to occur prior 
to enrollment will be dist inguished fro m those reported as new or increased in severit y during the 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 40
LY573144study .  Each symptom  will be classified by the most suitable term fro m the medical  regulatory  
dictionary.
The number of invest igational product -related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Clinical laboratory parameters, vi tal signs, and 12-lead ECG param eters will  be listed, and 
summarized using standard descript ive statist ics.  Addit ional analysis will be performed if 
warranted upon review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan , its metabo lites, and propranol olwill be 
calculated by standard noncompartmental methods of analysis.
The primary  parameters for analysis will be : Cmax, tmax,and AUC (
0-∞)oflasmiditan and i ts 
metabo lites on Days 1 and 9; and Cmax, tmax, and AUC τofpropranolo l on Days 8 and 9 .  Other 
nonco mpart mental param eters, such as half -life, apparent clearance, and apparent volume of 
distribut ion may be reported.
10.3.2.2. Pharmacokinetic Statistical Infere nce
Pharmacokinet ic parameters will be evaluated to determine the impact of propranolo l 
coadministration on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with a fixed effect 
for treatm ent(lasmidi tan coadministered wi th propranol ol [Day  9; test treatm ent] versus 
lasmiditan alo ne [Day 1; ref erence treatm ent]) , and a random effect for subject.  The treatment 
differences will be back -transform ed to present t he ratios of geometric means and the 
corresponding 90% CI.  
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference 
based on the observed medians, 90% CI s and p -values from the W ilcoxon test will be calculated .
A similar analysis will be performed to determine the impact of coadministration of a single dose 
of lasmidi tan on the steady -state PK of propranolo l.  The model will include the following 
treatm ents:propranolo l coadministered wi th lasmidi tan (Day 9; tes t treatm ent)versus 
propranolo l alone (Day 8; ref erence treatment).
Addit ional analyses m ay be performed, as warranted.
10.3.3. Cardiovascular Analyses
10.3.3.1. Cardiovascular Parameter Estimation
The primary  parameters for the cardi ovascular analyses will be systolic bloo d pressure, diastolic 
blood pressure, mean hourly heart rate, mean hourly heart rate nadirs, heart rate, and PR interval.  
Mean hourly  heart rates fro m 1 hour predose to 12 hours postdose will be calculated on Day s -1,
1, 8, and 9 from the Holter monitorin g data.  Negative chronotropic effects will be evaluated 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 41
LY573144using nadir (1–6 h), nadir ( >6 h–12 h), and nadir (1 –12h), which aredefined as the lowest mean 
hourly  heart rate during each postdose time period on each day .  Heart rate and PR interval will 
also be determined on Day s -1, 1, 8, and 9 from the 10-second Holter traces extracted at the time 
points listed in the Schedule of Activit ies(Secti on 2) .
Orthostatic changes in blood pressure and pulse rate will be determined at the time points listed 
in the Schedule of Act ivities (Section
 2)  
10.3.3.2. Statistical Inference of Cardiovascular Parameters
Cardi ovascular param eters will  be evaluated to determine the impact of coadministration of 
propranolo l with lasmidi tanon blood pressure ,heart rate, andPR interval co mpared to 
propranolo l alone.  
Primary cardi ovascular param eters will be evaluated in a l inear mixed -effects 
model with a fixed effect for treatment (lasmidi tan coadministered wi th propranol ol [Day  9; test 
treatm ent] versus pr oprano lol alone [Day 8; ref erence treatm ent]) , and a random effect for 
subject.  Least squares means will be calculated for the test and reference treatments.  Mean
treatm ent differences will be present ed, al ong with thecorresponding 90% CI.  Primary PD 
param eters m ay be log-transform ed pri or to the stati stical analysis if a review of the data 
indicates that the assumpt ion of normalit y is violated.
A similar analysis will be performed to determine the impact of coadministration of lasmiditan 
with proprano lol on bl ood pressure, heart rate, and PR interval compared to lasmiditan alone.  
The m odel will include the following treatments:  propranolo l coadministered wi th lasmidi tan 
(Day  9; test treatm ent) versus l asmidi tan al one (Day 1; reference treatm ent).
Theimpact of coadministration of propranolo l with lasmidi tan on orthostati c blood pressure and 
pulse rate will be evaluated using descriptive statistics as appropriate.  No formal statist ical 
analysis is planned.
10.3.4. Interim Analyses
No interim analyses are plan ned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly clinical pharmacologist, CRP /investigator, or designee will consult with the 
appropriate medical director or designee to determine if it is necessary to amend the protocol .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 42
LY57314411. References
Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinet ic interacti on between the 
antimigraine compound, almotriptan, and propranolo l in healt hy vo lunteers. Cephalalgia. 
2001;21(1):61 -65.
LeWinter MM, Crawford MH, Karliner JS, ORourke RA. Effects of oral propranolo l in norm al 
subjects. Clin Pharmacol Ther. 1975;17(6):709 -12.
Marathe PH, Greene DS, Kollia GD, Barbhaiya RH. A pharmacokinet ic interacti on study  of 
avitriptan and propranolo l. Clin Pharmacol Ther . 1998;63(3):367 -378.
Miners JO, Wing LMH, Lillywhite KJ, Robson RA. Select ivity and dose -dependency of the 
inhibitory  effect of propranolo l on theophylline metabolism in man. Br J Clin Pharmacol . 
1985;20:219 -223.
Peck RW, Seaber EJ, Dixon R, Gillot in CG, Weatherley BC, Layton G, Posner J. The interaction 
between propranolo l and the novel ant imigraine agent zolmitriptan (311C90). Br J Clin 
Pharmacol . 1997;44(6):595 -
599.
Scott AK, Walley  T, Breckenridge AM, Lacey LF, Fowler PA. Lack of an in teracti on between 
propranolo l and sumatri ptan. Br J Clin Pharmacol . 1991;32(5):581 -584.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 43
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 44
LY573144Term Definition
5-HT 5-hydroxy tryptamine (serotonin)
AE adverse event:  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or diseas e temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotranferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from zero to infinity
AUC τ area under the concentration versus time curve during 1 dosing interval
bid twice daily
BMI body mass index
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
Cmax maximum observed drug concentration
CNS central nervous system
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regula tory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immed iately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CPK creatine phosphokinase
CRP Clinical Research Physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 45
LY573144CRU clinical research unit
CV% coefficient of variation
CYP cytochrome P450
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
FSH follicle -stimulating hormone
GCP good clinical practice
GGT gamma -glutamyl transferase
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni sation
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documented by means of a 
written, signed and dated informed consent fo rm.  
Investigational 
product (IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way differen t from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.   If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IV intravenous
LC-MS/MS liquid chromatography with tandem mass spectrometric detectio n
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 46
LY573144LS least squares
Non-
investigational 
product (non -IP)A product that is not being tested or used as a reference in the clinical study, but is provided 
to subjects and used in accordance with the protocol, such as:  concomitant or rescue/escape 
medication for preventative, diagnostic, or therapeutic reasons, medication to ensure 
adequate medical care, and/or products used to induce a physiological response.
open -label A study  in which there are no restrictions on knowledge of treatment allocatio n, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PK pharmacokinetic
QTc corrected QT interval
randomize the process of assigning subjects to an experimental group on a random basis
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.   
SUSARs suspected unexpected serious adverse reactions 
TBL total bilirubin
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state , and does not necessarily have to have a causa l relationship with this 
treatment 
Tmax time of maximum observed drug concentration
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 47
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Gluco se (random)
Platelets Blood urea nitrogen (BUN)
Differential WBC absolute counts and % of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Creatinine
Urinaly sis
Specific gravity
pH
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Bilirubin Hepatitis B surface antigen a
Urobilinogen Hepatitis C antibody a
Blood HIV a
Nitrite Serum pregnancy test (females only) d
Urine microscopic (if positive result for blood) FSH (females only, if applicable) c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
WBC = white blood cells.
aPerformed at screening only .
bUrine drug screen and ethanol level will be performed locally at screening and may be repeated prior to 
admission to the clinical research unit and at other times indicated in the Schedule of Activities (Section 2).  
cPerformed at screening only, for confirmation of postmenopausal status .
dPerformed at screening only, Day -
1, and follow -up only .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 48
LY573144Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  This
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product .
answering any quest ions the subject may  have throughout the study  and sharin g in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file.
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by Internat ional Council for Harmonisat ion (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i tis used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulato ry Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 49
LY5731443)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
Final Report Signature
The invest igator or designee will sign the clinical study report for this study , indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of hi s or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs, and study  procedures.
make periodic visit s to the study  site.
be availabl e for consul tation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or i ts representatives willperiodically check a sample of the subject d ata 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before a n audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applica ble ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 50
LY573144Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal informat ion collected will be provided in a written 
docum ent to the subject by the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be disco ntinued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable law s, regul ations, and GCP.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 51
LY573144Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abno rmality and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 52
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, clinical laboratory  tests ,and bioanalyt ical assays) during the study .  
Proto col H8H -MC -LAHD Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 6 75
Lasmiditan and metabolite PKb 2 31 62
Propranolol PK b 4 23 92
Pharmacogenetics 10 1 10
Total 258.5
Total for clinical purposes (rounded up to the nearest 10 mL ) 260
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 53
LY573144Appendix 6. Protocol A mendment H8H-MC-LAHD(a) 
Summary : Effect of Lasmiditan on Heart Rate and Blood 
Pressure in Healthy  Subjects Receiving Oral Doses of 
Propra nolol
Overview
Protocol  H8H -MC-LAHD ,Effect of Lasmiditan on Heart Rate and Blood Pressure in Healt hy 
Subjects Receiving Oral Doses of Propranolo l,has been amended.  The new protocol is indicated 
by Amendment (a) and will be used to conduct the study  in place of any preceding versio n of the 
protocol .
The overall changes and rationale for the changes made to this protocol are as fo llows:
Following feedback from the FDA from the Type C m eeting on 12 October 2017, the 
protocol  was amended to include an assess ment o flasmiditan metabo lites. 
Subjects should be admitted to the CRU on Day  -2. The l anguage in Section 5.1 has been 
updated to remove contradictory  informat ion that preceded “Day -2”. 
Clinical laboratory  assessments and genet ic sampling in the Schedule of Activit ies shoul d 
be perform ed on Day  -2 to allow determination o f a dosing order prior to Holter 
monitoring on Day  -1. 
Pregnancy tests are required only at screening, Day  -1, and the follow up visit ;thesafet y 
laboratory  test appendix was updated accordingly .
Subjects should be excluded fro m the study  if they have orthostati c decreases in systolic 
blood pressure of >20 mmHg, not supine blood pressure as is st ated i n the ori ginal  
protocol .
The al coho l restri ction in this study should be observed fro m 48 hours prior to CRU 
admissio n and unt il discharge from the CRU, as described in Sect ion 6.3.2. The 
exclusio n criterion was updated to be consistent with this language.
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 54
LY573144Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
1. Protocol Synopsis
Summary of Study Design :  
This is an open -label, fixed -sequence study in healthy subjects to assess the cardiovascular effects of the 
coadministration of lasmiditan with propranolol.  Subjects will receive a single dose of 200 mg lasmiditan on Day 1, 
then receive a single dose of 200 mg lasmiditan coadministered with steady -state propranolol on Da y 9.
Blood samples will be collected predose and up to 48 hours postdose on Days 1 and 9 for the measurement of 
plasma concentrations of lasmiditan and its metabolites , and predose and up to 12 hours postdose on Days 8 and 9 
for the measurement of plasma concentrations of propranolol.
Statistical Analysis:
Pharmacokinetic parameter estimates for lasmiditan , itsmetabolites, and propranolol will be calculated by standard 
noncompartmental methods of analysis.
Pharmacokinetic parameters will be evaluated to d etermine the impact of propranolol coadministration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C max and AUC parameters will be evaluated in a 
linear mixed-effects model with a fixed effect for treatment (lasmiditan coadm inistered with propranolol [Day 9; test 
treatment] versus lasmiditan alone [Day 1; reference treatment]), and a random effect for subject.  The treatment 
differences will be back -transformed to present the ratios of geometric means and the corresponding 90 % CI.  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 55
LY5731442. Schedule of A ctivities
Study Schedule Pro tocol H8H -MC-LAHD
ScreeningStudy DaysFollow -
up/EDComments
Procedure-28 to -3
days prior 
to Day 1-2 -1 1 2 3 4 5 6 7 8 9 10 11~7 day s 
post last 
dose
Clinical Lab 
Tests
(including 
serum 
pregnancy 
test)X X X X X X XSeeAppendix 2 , 
Clinical Laboratory 
Tests, for details.   If 
multiple procedures 
take place at the same 
time point, the 
following order of the 
procedure sshould be 
used: ECG, vital signs, 
and venipuncture . 
Genetic 
SampleX XSingle sample for 
pharmacogenetic 
analy sis taken prio r 
to/on Day  1
Lasmiditan 
and Metabolite 
PK Samples 
(hours) Predose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 1224, 
3648Predose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 1224, 
3648Sampling times are 
relative to the time of 
study treatment
administration (0 min).
If multiple procedures 
take place at the same 
time point, the 
following order of the 
procedure sshould be 
used: ECG, vital signs, 
and venipuncture .
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 56
LY5731443.2. Background
Two Phase 2 studies have been co mpleted wi th lasmidi tan in the acute treatm ent of migraine, 
using doses of up to 45 mg over 20 minutes of the IV formulat ion, and up to 400 mg of the oral 
tablet formulation.  One Phase 3 rando mized, double -blind, placebo controlled trial has been 
completed in the United States (COL MIG -301 [SAMURAI]), where 1856 patients were 
rando mized to 100 mg lasmiditan (630 subjects), 200 mg (609 subjects), or placebo 
(617 subjects), respectively. In the SAMURAI study ,both 100 m g and 200 m g doses of orally 
administered lasmiditan achieved superior 2- hour pain free rate and the relief o f most 
bothersome migraine symptoms (nausea, phonophobia, and photophobia) compared to placebo.
Across the completed Phase 1, 2, and 3 c linical studies, doses of 0.1 mg to 400 mg o f lasmiditan 
were evaluated in healt hy subjects or patients with migraine.  Lasmiditan has been administered 
to 213 healthy subjects in five Phase 1 studies:  as IV doses ranging from 0.1 to 180 mg 
(H8H -MC-LACA; 40 subjects); as an oral or sublingual so lution with doses ranging from  25 to 
400mg and 1 to 32 mg, respectively (COL MIG -102; 60 subjects); as an oral solut ion at a dose 
of 200 mg or as oral tablets at doses of 50 or 400 mg (COL MIG -103; 44 subjects); as oral 
tablets at a dose of 200 mg (COL MIG -104; 30 subjects); and as oral tablets at doses of 100 or 
400mg (COL MIG -105; 56 subjects).  Two Phase 2 studies have been co mpleted, evaluat ing IV 
doses ranging fro m 2.5 to 45 mg (COL MIG -201) and oral tablets ranging from 50 to 400 mg 
(COL MIG -202).  In the Phase 3 SAMURAI study (COL MIG-301), 1856 patients aged 18 to 
79years received at least 1 dose of lasmiditan or placebo, with 1239 patients receiving oral 
tablets of  100 or 200 mg lasmiditan.  The most frequ ently reported lasmiditan treatment -
emergent adverse events (TEAEs) included dizziness (12.5 to 16.3%), paresthesia (5.7 to 7.9%), 
somno lence (5.4 to 5.7%), fat igue (3.1 to 4.1%), , and, compared to placebo where 3.4%, 2.1%, 
2.3%, and 0.3% of subjects repo rted each event, respect ively.  The majorit y of these TEAEs 
were mild or moderate in severit y and none led to subject withdrawal.  
Oral tablet doses of lasmiditan up to 400 mg did not result in any clinically relevant changes in 
ECGs (including QT interval/corrected QT interval [QTc]) or vital signs fo llowing 
administration to healthy subjects.  There was a consistent small decrease in heart rate at oral 
doses of 100 to 400 mg lasmiditan though this was not considered to be clinically significant 
(COL MIG -102, COL MIG -103, COL MIG -105).  A single SAE of dizziness wit h sinus 
bradycardia after an oral dose of 200 mg lasmiditan was reported; this event was moderate in 
severit y, occurred approximately 30 minutes after dosing wit h lasmidi tan 200 mg, and was 
considered to be probably related to lasmiditan.  The subject was admitted to hospital for 
overnight observation fo llowing review by the hospital emergency  room  physician.
In the thorough QT study  (COL MIG -105) in healthy  subjects, no clinically significant ch anges 
in blood pressure, heart rate, or 12 -lead ECG were observed at the 100 or 400 mg dose levels.  
Lasmiditan caused no significant QT prolongat ion at ei ther dose.
In healthy subjects, peak plasma concentrations of lasmiditan were observed approximately 1 to 
2.5 hours after a single oral doses ranging from 25 to 400 mg, and the geometric mean terminal 
half-life was approximately 4 to 6 hours.  Lasmidit an exhibited dose -linear PK; low to moderate 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 57
LY573144inter-subject variabilit y in exposure was observed across do ses (coefficient of variat ion [%CV]
up to 61% and 45% for maximum observed drug concentration [Cmax] and area under the curve 
[AUC], respectively (COL MIG -102).  Renal clearance of lasmiditan was low, with 
approximately  2% of  the parent dose recovered by  24 hours postdose.  Co-administration of 
lasmiditan wit h a high fat diet led to a delay in median time o f maximum observed drug 
concentration (t max) value by approximately  1 hour and a m odest (~20%) increase in lasmiditan 
maximum observed drug concentration (Cmax) and AUC values, relative to that under fasted 
condi tions.    
Hum an metabolism has been invest igated using liquid chromatography  with tandem mass 
spectrometric detection ( LC-MS/MS )following oral  dosing wi th lasmidi tan, where up to 11 
metabo lites were detected i n plasma and urine, including 3 major metabo lites (M7, M8, and 
M18).  These metabolites lacked significant pharmacological act ivity at the 5 -HT 1Freceptor and 
were generally  considered to be pharm acologically inact ive.  The relat ive proporti ons of 
metabo lites to intact l asmidi tan remained reasonably  constant throughout the oral dose range 
studi ed and thei r PK w asapproximately linear.  The half -life o f the metabo lites ranged from  
~4.5 hours to >12 hours.
4. Objectives and Endpoints
Table LAHD.1 shows the object ives and endpo ints of the study .
Table LAHD. 1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effects of propranolol alone and in 
combinatio n with lasmiditan on heart rate.Heart rate by Holter ambulatory monitoring.
Secondary
To evaluate the effects of propranolol alone and in 
combinatio n with lasmiditan on blood pressure and PR 
interval.
To explore the tolerability of a single dose of lasmiditan 
alone o r in combination with propranolol.
To evaluate the PKof lasmiditan alone and in 
combinatio n with propranolol .
To evaluate the PKof propranolol alone and in 
combinatio n with lasmiditan .PR interval by Holter ambulatory monitoring, systolic 
blood pressure, and diastolic blood pressure.
A summary of the number of TEAEs and SAEs .
Cmax, tmax, and AUC(0 -∞).
Cmax, tmax, and AUC during 1 dosing interval ( AUC τ).
Exploratory Objectives
To evaluate the effects of lasmiditan alone and in Orthostatic changes in systolic blood pressure, diastolic 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 58
LY573144combinatio n with propranolol on orthostatic change s in 
blood pressure and pulse rate.blood pressure, and pulse rate.
To evaluate the PK of the metabolites M8, M7, and M18 
in healthy  subjects following a single 200 -mg oral dose 
of lasmiditan alone and in combination with propranolol .PK parameters:  C max, tmax, and AUC(0 -∞)
5.1. Overall Design
This is an open -label , fixed -sequence study  in healthy  subjects to assess the cardiovascular 
effects of coadministration of lasmiditan with proprano lol. 
Screening Period: 
All subjects will part icipate in a screening visit up to 28 days prior to the first lasmiditan dose.  
Dosing Period:
Subjects will be admitted to the clinical research unit (CRU) on the day  prior to dosing ( Day -2).  
On Day  1, subjects will receive a single dose of 200 m g lasmiditan, then receive propranolo l 
(immediate release formulation; half -life approximately 3 to 6 hours) 80 mg bid on Days 4
through 10and a single dose of 200 m g lasmiditan coadministered with propranolo l on Day  9.  
Subjects will reside in the CRU from Day -2 unt il Day 11 when they  may be discharged from the 
CRU following com pletion of all study  procedures , at the investigator’ s discret ion.
Study  governance considerations are described in d etail in Appendix 3 .
Blood sam ples will be collected predose and up to 48 hours postdose on Days 1and 9for the 
measurement of plasma concentrations of lasmidi tanand i ts metabo lites. Blood sam ples will 
also be collected predose and up to 12 hours postdose on Day s 8 and 9 for the m easurement of 
plasma concentrations of propranol ol.
6.2. Exclusion Criteria
[16] have a history  of syncope, presyncope, uncontrolled vertigo, postural dizzine ss, or at risk 
for falls, as j udged to be clinically  significant by  the invest igator, or have orthostatic decreases in 
supine systolic blood pressure of >20 mmHg, or have orthostatic decreases in diastolic blood 
pressure of >10 mmHg at screening.  May be r epeated if asymptomat ic.
[30] have an average weekly  alcoh ol intake that exceeds 21 units per week (males agedup to
65years ) and 14 unit s per week (females and males over 65 years), or are unwilling to stop 
alcoho l consumpt ion 48 hours prior to dosing until the complet ion of the study and whilst 
resident at the CRU.  At all other times, subjects must consume no more than 2 units per day (1 
unit = 12 oz or 360 mL of beer; 5 oz or 150 mL o f wine; 1.5 oz or 45 mL of dist illed s pirits).
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2) , venous blood samples 
of approximately  2mL each will  be collected to determine the plasma concentrations of 
lasmiditan and its metabolites, and venous blood samples of approximately  2 mL each will  be 
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 59
LY573144collected to determine the plasma concentrations of proprano lol.  A maximum of 3 samples each 
may b e collected for analysis of lasmiditan or proprano lol at addi tional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor .  
The actual  date an d time (24- hour clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of lasmiditan and 3majo r metabo lites will be assayed using a validated liquid 
chromatography  with tandem  mass spectrom etric detection ( LC-MS/MS )method. 
Concentrations of propranol ol will be assayed using a validated LC-MS/MS m ethod. 
Bioanaly tical samples collected to m easure invest igational product and metabolite concentrati ons 
will be retained for a maximum o f 2 years fo llowing last subject visit for the study .  During this 
time, samples remaining after the bioanalyses may be used fo r expl oratory  analyses such as 
metabo lism and/or protein binding work.
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan , its metabo lites, and propranol ol will be 
calculated by standard noncompartmental metho ds of analysis.
The primary  parameters for analysis will be:  C max, tmax, and AUC(0 -∞) of l asmidi tan and its 
metabo lites on Day s 1and9; and Cmax, tmax, and AUC τof propranolo l on Days 8 and 9.  Other 
nonco mpart mental param eters, such as half -life, appare nt clearance, and apparent volume of 
distribut ion may be reported.
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameters will be evaluated to determine the impact of propranolo l 
coadministration on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with a fixed effect 
for treatm ent(lasmidi tan coadministered wi th propranol ol [Day  9; test treatm ent] versus 
lasmiditan alo ne [Day 1; ref erence treatm ent]) , and a random effect for subject.  The treatment 
differences will be back -transform ed to present the ratios of geometric means and the 
corresponding 90% CI.  
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the media n difference 
based on the observed medians, 90% CI s and p -values from the W ilcoxon test will be calculated.
A similar analysis will be performed to determine the impact of coadministration of a single dose 
of lasmidi tan on the steady -state PK of propranolo l.  The model will include the fo llowing 
treatm ents:  propranolo l coadministered wi th lasmidi tan (Day  9; test treatm ent) versus 
propranolo l alone (Day 8; ref erence treatment).
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 60
LY573144Addit ional analyses m ay be performed, as warranted.
Appendix 2. Clinical Laborat ory Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Gluco se (random)
Platelets Blood urea nitrogen (BUN)
Differential WBC absolute counts and % of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Creatinine
Urinaly sis
Specific gravity
pH
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Bilirubin Hepatitis B surface antigen a
Urobilinogen Hepatitis C antibody a
Blood HIV a
Nitrite Serum pregnancy test (females only) d
Urine microscopic (if positive result for blood) FSH (females only, if applicable) c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
WBC = white blood cells.
aPerformed at screening only .
bUrine drug screen and ethanol level will be performed locally at screening and may be repeated prior to 
admission to the clinical research unit and at other times indicated in the Schedule of Activities (Section 2).  
cPerformed at screening only, for confirmation of postmenopausal status.
dPerformed at screening only, Day  
-1, and follow -up only .
Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, clinical laboratory  tests, and bioanalyt ical assays) during the study .  
H8H-MC-LAHD (a)Clinical P harmacology Protocol Page 61
LY573144Proto col H8H -MC -LAHD Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 6 75
Lasmiditan and metabolite PKb 2 31 62
Propranolol PK b 4 23 92
Pharmacogenetics 10 1 10
Total 258.5
Total for clinical purposes ( rounded up to the nearest 10 mL) 260
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.